The Lizard in Your Pen

The lizard does not have a wedding, which is rather the point. Somewhere in the creased badlands of Arizona and New Mexico there is a fat, slow, venomous creature called Heloderma suspectum, the Gila monster, who has been eating the same stupid meals since long before anyone invented a destination wedding, going months between meals and then, when opportunity presents itself, swallowing an indecent fraction of its own body weight. In its salivary glands it manufactures a thirty-nine-amino-acid peptide called exendin-4, which enters the story because it happens to speak remarkably good mammalian metabolism. What exactly exendin-4 is doing for the Gila monster itself remains an evolutionary argument: its blood levels can rise after feeding and vigorous biting, but experiments have not shown that it controls the lizard’s post-meal glucose the way it does ours. Nature, irritatingly, did not write the explanatory leaflet. What she did write was a molecule that could turn on the mammalian GLP-1 receptor and survive long enough to matter, which turned out to be much more useful to us than whatever private reptilian business it had originally evolved to conduct.

I have spent fifteen years in American healthcare research, long enough to have watched a molecule travel from a Bronx VA hospital bench to a wedding trousseau list, so I know the distance between a lizard’s mouth and your mother’s approval is shorter than you think and considerably more humiliating than it looks. In 1992 Dr. John Eng, working at the Veterans Affairs Medical Center in the Bronx, isolated exendin-4 from Gila-monster venom while following a trail laid by earlier NIH work showing that compounds in the venom could strongly stimulate pancreatic cells. Eng found that the peptide resembled, without being identical to, a human gut hormone called glucagon-like peptide-1, or GLP-1, the one your own intestines release after you eat to say here is some glucose, make insulin if glucose is high, restrain the glucagon, slow things down, and perhaps put the fork away for a minute. The trouble with native human GLP-1 is that an enzyme called DPP-4 shreds it with bureaucratic efficiency; its circulating half-life is roughly one or two minutes, a lifespan so brief it could be called a tantrum. Exendin-4, by contrast, resists that particular executioner. So we did what humans do when a reptile has accidentally written useful pharmacology: we copied it, industrialized it, and sold it back to ourselves through a prescription pad.

That direct lizard lineage produced exenatide, sold as Byetta and approved in the United States in 2005, essentially a synthetic version of exendin-4. Then the family tree branches, and this distinction matters because otherwise the Gila monster gets intellectual property credit it did not earn. Semaglutide, the active ingredient in Ozempic and Wegovy, is not synthetic Gila-monster venom and is not descended chemically from exendin-4; it is an engineered analogue of human GLP-1, altered so that it survives in the body for about a week. Tirzepatide, Eli Lilly’s Mounjaro, wanders even farther from the reptile: it activates both the GIP and GLP-1 receptors. The Gila monster did not father every injection pen in the pharmacy. What it helped establish was that you could make GLP-1-receptor signaling durable enough to become a drug, and from that peculiar biological hint grew an industry large enough to require its own accountants, lobbyists, refrigerators and bridal packages.

Semaglutide reduces appetite and calorie intake and delays gastric emptying, particularly while doses are being increased, which is a polite pharmacological way of saying it can turn the stomach into a bouncer. Food arrives at the velvet rope, the brain looks at the queue, and somebody inside says we are at capacity.

The word appetite comes through Latin appetitus, longing or desire, from appetere: to seek after, to strive for, to grasp at. Not originally to eat, exactly, which makes the word better rather than worse, because hunger was never merely a hole in the stomach. It is wanting with an address. The whole pharmaceutical enterprise is sitting inside that etymology: a molecular signal that modifies wanting, sold in a pen, bought as rescue, medicine, vanity, metabolic correction or panic depending on who is holding the receipt.

And here the story leaves the desert and falls off a cliff into India, because India, as usual, encountered a molecule that was expensive, exotic and quietly revolutionary and immediately began arguing about how cheaply it could manufacture it.

In March 2026 the principal Indian patent protection on semaglutide reached the end of the road, and the country’s generic-drug machine began making the sound that heavy machinery makes just before somebody loses market share. India produces roughly sixty thousand generic brands across about sixty therapeutic categories and accounts for around a fifth of global generic-drug exports by volume, so this was never going to be a dignified transition. More than forty Indian companies were expected to produce over fifty semaglutide brands. Natco came out at the patent cliff with multidose-vial versions priced from about ₹1,290 a month; Glenmark arrived with GLIPIQ, Dr. Reddy’s with Obeda, Sun Pharma with Noveltreat and Sematrinity, and Zydus, Torrent, Alkem, Eris and the rest began filling the shelves the way ants appear on a dropped laddu. Some came in vials, some pens, some oral formulations, some aimed at diabetes and some at obesity, because even the molecule now needed a caste system.

Novo Nordisk responded by cutting Indian prices from April 1. The lowest monthly dose of Ozempic and Wegovy fell to about ₹5,660, while higher doses still climbed well into five figures. Indian generics undercut even that, some dramatically. So within weeks the economic meaning of semaglutide changed. It had not become cheap in the sense that onions are cheap or paracetamol is cheap; it had become reachable, which in India is a much more dangerous commercial category. A luxury can be ignored. A temptation has an EMI.

What nobody prices in, of course, is the wedding.

Somewhere in New Delhi, Klarity Skin Clinic began advertising something called, and I am transcribing this like a coroner reading out a cause of death, the Mounjaro bride. Its own pitch combined Mounjaro with guided nutrition and workouts, while other clinics were folding the injections into the wider Indian pre-wedding transformation bazaar of skin treatments, hair, body sculpting and the ancient matrimonial project of replacing the woman who became engaged with an improved export-quality version before the photographer arrives. Reuters spoke to doctors across India who said brides and grooms were increasingly turning up asking about obesity injections with wedding dates attached. Bariatric surgeon Rajat Goel in New Delhi said more than twenty percent of the obesity-injection inquiries at his practice in recent months had come from brides-to-be.

This is a remarkable way to present a medical history. No hypertension, no sleep apnea, no HbA1c, no family history: December 14, doctor, and the lehenga has already been ordered.

Goel says he prescribes the drugs only when patients are medically eligible and not merely for cosmetic weight loss, which is a sensible sentence being forced to operate in an increasingly nonsensical ecosystem. India’s regulator has not been entirely asleep. In March the Central Drugs Standard Control Organisation warned drugmakers against direct or surrogate advertising of prescription obesity drugs to the public, and regulators inspected dozens of online-pharmacy warehouses, wholesalers, retailers and wellness or slimming clinics after concerns about on-demand sales and improper prescribing. So the market is not exactly unregulated. That would almost be simpler. It is regulated on paper, medically legitimate at its center, commercially explosive at its edges, and surrounded by that peculiarly Indian penumbra where a rule can be perfectly clear while reality strolls around it carrying a shopping bag.

And the legitimate need is enormous. The ICMR-INDIAB study estimated roughly 101 million people in India were living with diabetes and another 136 million with prediabetes. A major Lancet analysis projected that by 2050 roughly 450 million Indian adults aged twenty-five and older could be living with overweight or obesity. These are not cosmetic numbers. GLP-1 and related incretin drugs are among the most consequential metabolic medicines developed in decades, and reducing them to celebrity waistlines would be as stupid as reducing penicillin to acne.

But consequence is not innocence. These drugs are powerful precisely because metabolism is powerful. Nausea, vomiting, diarrhea and constipation are common; gallbladder disease and pancreatitis are less common but clinically serious concerns. Substantial weight loss can take lean tissue with it as well as fat, as substantial weight loss often does, which is why adequate protein and resistance exercise are the dreary unphotogenic companions nobody puts on the Instagram reel. And stopping treatment does not mean the body’s old regulatory machinery has signed a surrender treaty. In the extension of the STEP 1 semaglutide trial, participants regained about two-thirds of the weight they had lost within a year of stopping treatment. The lizard gave us a way to manipulate the argument with hunger and metabolism. It did not repeal either one.

I keep coming back to the monster because the monster is the only character in this story who has not hired a marketing agency. It eats rarely, stores what it can, survives an environment that does not guarantee lunch, and manufactures a peptide whose original job we still do not completely understand. That uncertainty makes the story better, not worse. We did not simply discover that a desert lizard had solved obesity for us. We found a strange molecular key in its saliva, noticed that the key opened one of our locks, and built an enormous therapeutic architecture around the coincidence.

That is more like science anyway. Less Archimedes in the bath, more burglar with a ring of keys.

We took a molecule shaped by scarcity and folded its lesson into a civilization where abundance itself has begun producing disease. That is not a category error; obesity and diabetes are real chronic diseases, not moral failures and not inventions of Novo Nordisk’s marketing department. But neither is every unwanted kilogram a disease, and somewhere between those two facts sits the bride with six weeks to go, scrolling through reels at two in the morning, looking at a body that has suddenly become a project plan.

The wedding invitation has become a clinical deadline.

The Taittiriya Upanishad has Bhrigu, searching for Brahman, first arrive at अन्नं ब्रह्मेति व्यजानात् — annam brahmeti vyajānāt — he understood food as Brahman. The inquiry does not actually stop there; Bhrigu keeps going through breath, mind, understanding and bliss, because even the Upanishads were suspicious of slogans. Still, imagine the nerve of putting food at the entrance to metaphysics, of treating nourishment not as an enemy appetite to be disciplined into silence but as one of the first doors through which existence becomes intelligible.

And now, several thousand years later, we have put the door on a weekly injection schedule.

So go ahead and inject your way down the aisle if you medically need the drug, my dear, and perhaps do not if the principal diagnosis is that the photographer has been booked. Somewhere in the Sonoran Desert a slow venomous reptile is chewing whatever it has managed to find, carrying in its saliva a molecule whose purpose it has never explained to us. It has no wedding date, no target weight, no before photograph, no mother measuring its waist, no dermatologist selling it a package, and no idea that part of its molecular machinery ended up inside one of the great medical and commercial dramas of the twenty-first century.

The lizard never asked to be thin.

It merely taught us, accidentally, how complicated hunger was.

P.S. References: John Eng et al., “Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom,” Journal of Biological Chemistry (1992); Raufman et al., early NIH work on Gila-monster venom and pancreatic secretion; Christel and DeNardo, studies of exendin-4 release and physiology in Gila monsters; Reuters, “Mounjaro brides: weight-loss drugs make foothold in pre-wedding prep” (April 2026); Reuters coverage of India’s semaglutide patent expiry, generic launches and price cuts (March–April 2026); CDSCO / Government of India advisories on GLP-1 promotion and distribution (March 2026); ICMR-INDIAB national diabetes estimates; The Lancet, global overweight and obesity forecasts to 2050; Wilding et al., STEP 1 semaglutide withdrawal extension.